Darunavir/cobicistat
Darunavir/cobicistat, sold under the brand names Prezcobix (US) and Rezolsta (EU), is a fixed-dose combination antiretroviral medication used to treat and prevent HIV/AIDS. It contains darunavir and cobicistat. Darunavir is an HIV protease inhibitor and cobicistat increases the effectiveness of darunavir by blocking its metabolism by the enzyme CYP3A.
Combination of | |
---|---|
Darunavir | HIV protease inhibitor |
Cobicistat | Cytochrome P450 (CYP3A) inhibitor |
Clinical data | |
Trade names | Rezolsta, Prezcobix |
AHFS/Drugs.com | Professional Drug Facts |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
PubChem CID | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C67H90N10O12S3 |
Molar mass | 1323.70 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
|
Darunavir/cobicistat was approved for use in the European Union in November 2014, and for use in the United States in January 2015.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.